AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

上周五，英国制药巨头阿斯利康（AstraZeneca, NASDAQ:AZN）宣布与中国石药集团（CSPC Pharmaceutical）达成一项潜在价值高达53.3亿美元的战略研究合作，旨在利用人工智能（AI）开发针对多种慢性疾病的新型口服疗法。

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...